Q2 EPS Forecast for CRISPR Therapeutics Decreased by Analyst

CRISPR Therapeutics AG (NASDAQ:CRSP) – Equities researchers at William Blair lowered their Q2 2025 earnings per share estimates for CRISPR Therapeutics in a research report issued on Wednesday, May 7th. William Blair analyst S. Corwin now forecasts that the company will earn ($1.10) per share for the quarter, down from their prior estimate of ($1.01). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.16) per share. William Blair also issued estimates for CRISPR Therapeutics’ Q3 2025 earnings at ($1.08) EPS, Q4 2025 earnings at ($1.08) EPS, FY2025 earnings at ($4.85) EPS, Q1 2026 earnings at ($0.91) EPS, Q2 2026 earnings at ($0.87) EPS, Q3 2026 earnings at ($0.73) EPS, Q4 2026 earnings at ($0.65) EPS and FY2026 earnings at ($3.16) EPS.

Other equities analysts also recently issued reports about the company. Truist Financial boosted their price objective on CRISPR Therapeutics from $100.00 to $120.00 and gave the company a “buy” rating in a research report on Wednesday, February 12th. JMP Securities restated a “market outperform” rating and set a $86.00 target price on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. TD Cowen upgraded CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 price target for the company in a research report on Wednesday, February 12th. Needham & Company LLC dropped their target price on CRISPR Therapeutics from $84.00 to $81.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, Barclays lowered their target price on shares of CRISPR Therapeutics from $56.00 to $42.00 and set an “equal weight” rating for the company in a research note on Friday. Two analysts have rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $71.75.

CRISPR Therapeutics Price Performance

CRSP opened at $35.62 on Friday. CRISPR Therapeutics has a 1-year low of $30.04 and a 1-year high of $67.88. The company has a 50 day simple moving average of $38.15 and a two-hundred day simple moving average of $42.75. The firm has a market cap of $3.08 billion, a P/E ratio of -8.15 and a beta of 1.88.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. During the same period in the prior year, the firm earned ($1.43) earnings per share. The business’s revenue for the quarter was up 71.6% on a year-over-year basis.

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 9,973 shares of the firm’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $423,054.66. Following the completion of the sale, the chief executive officer now owns 180,890 shares of the company’s stock, valued at approximately $7,673,353.80. This trade represents a 5.23 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director John Greene bought 7,000 shares of the company’s stock in a transaction on Wednesday, February 26th. The shares were bought at an average cost of $44.85 per share, for a total transaction of $313,950.00. Following the transaction, the director now owns 7,000 shares in the company, valued at $313,950. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders sold 32,381 shares of company stock valued at $1,608,243. Corporate insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Costello Asset Management INC acquired a new position in CRISPR Therapeutics in the first quarter valued at approximately $27,000. Wood Tarver Financial Group LLC acquired a new stake in CRISPR Therapeutics during the 4th quarter worth $30,000. Ameriflex Group Inc. purchased a new stake in CRISPR Therapeutics during the 4th quarter valued at about $36,000. Highline Wealth Partners LLC acquired a new stake in shares of CRISPR Therapeutics in the fourth quarter valued at approximately $39,000. Finally, Western Pacific Wealth Management LP increased its stake in shares of CRISPR Therapeutics by 100.0% in the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock worth $39,000 after acquiring an additional 500 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.